Skip to main content
Clinical Trials/NCT07065916
NCT07065916Enrolling By InvitationNot Applicable

Arm More + Camp: An Implementation Study of a Modified Constraint Induced Movement Therapy Camp for Children With Hemiparesis

University of Calgary1 site in 1 country40 target enrollmentStarted: July 9, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Enrollment
40
Locations
1
Primary Endpoint
Implementation Cost

Study Overview

Brief Summary

Our primary aim is to evaluate the implementation cost of a full day modified constraint induced movement therapy camp for children with hemiparesis.

Participants will complete a day camp (9am to 4pm) with constraint induced movement therapy in Week 1 and bimanual therapy in Week 2.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
5 Years to 17 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Mild to moderate hemiparesis due to cerebral palsy or acquired brain injury (e.g, traumatic brain injury, stroke)
  • •Ability to actively extend wrist to neutral and actively flex and extend fingers (at minimum)
  • •Attend school full-time
  • •Able to participate in group activities
  • •Written consent

Exclusion Criteria

  • •Severe hemiparesis due to cerebral palsy or acquired brain injury
  • •No wrist movement on the hemiplegic hand.
  • •Unable to concentrate for periods of 60-90minutes

Arms & Interventions

Modified Constraint Induced Movement Therapy

Other

Constraint Induced Movement Therapy and Bimanual Therapy

Intervention: Modified Constraint Induced Movement Therapy (Behavioral)

Outcomes

Primary Outcomes

Implementation Cost

Time Frame: From enrolment to the end of outcome data collection at 3 weeks

Implementation cost covers all resources necessary, including personnel, time, space, and supplies.

Secondary Outcomes

  • Canadian Occupational Performance Measure(Baseline and the end of treatment at 2 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Adam Kirton

Pediatric Neurologist

University of Calgary

Study Sites (1)

Loading locations...

Similar Trials